Akari Therapeutics to Present at Biotech Showcase™ 2023
NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari President and CEO Rachelle Jacques will present a company overview at Biotech Showcase 2023 on Monday, January 9, 2023 at 9 am ET. The presentation will include progress highlights from Akari’s two priority pipeline programs: a Phase 3 clinical trial of nomacopan, a novel bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), for the treatment of severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, and a pre-clinical program investigating long-acting PAS-nomacopan as a potential treatment for geographic atrophy.
About Akari Therapeutics
Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari's lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akari's pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Akari has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA for nomacopan for the treatment of pediatric HSCT-TMA. Akari’s pipeline also includes pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit akaritx.com.
Investor Contact:
Mike Moyer
LifeSci Advisors
(617) 308-4306
mmoyer@lifesciadvisors.com
Media Contact:
Eliza Schleifstein
Schleifstein PR
(917) 763-8106
eliza@schleifsteinpr.com
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Dlaboratory Sweden AB (publ) delårsrapport januari – mars 20243.5.2024 11:30:00 CEST | Pressemelding
Lund, 3 maj 2024 Dlaboratory Sweden AB (publ) ("dLab" eller ”Bolaget”) offentliggör idag, den 3 maj 2024, delårsrapport för perioden 1 januari till 31 mars 2024. Den fullständiga rapporten som bifogas i pressmeddelandet kan även laddas ner från Bolagets hemsida: https://dlaboratory.com/sv/investors/. "Årets inledning har varit stabil och i linje med våra förväntningar, där innovation och nya produkter fortsätter att prägla vår verksamhet." – Rickard Jacobson, VD Dlaboratory Sweden AB (publ) Första kvartalet 2024 Nettoomsättningen uppgick till 7 176 (5 845) KSEK.EBITDA uppgick till -3 351 (-5 521) KSEK.Soliditeten uppgick till 47 (63) procent.Genomsnittligt antal aktier 16 944 976 (16 944 976).Resultat per aktie uppgick till -0,24 (-0,37) SEK. Händelser under perioden Den 29 februari offentliggjorde dLab bokslutskommunikén för perioden 1 januari till 31 december 2023. Den fullständiga rapporten kan laddas ner från Bolagets hemsida: https://dlaboratory.com/sv/investors/ Händelser efter p
UPM-Kymmene Corporation: Managers’ Transactions (Kekki)3.5.2024 11:30:00 CEST | Press release
UPM-Kymmene Corporation Managers’ Transactions 3 May 2024 at 12:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Kekki) UPM-Kymmene Corporation has on 3 May 2024 received the following notification: ____________________________________________ Person subject to the notification requirement Name: Mika Kekki Position: Other senior manager Issuer: UPM-Kymmene Corporation LEI: 213800EC6PW5VU4J9U64 Notification type: INITIAL NOTIFICATION ____________________________________________ Transaction date: 2024-05-03 Outside a trading venue Instrument type: SHARE ISIN: FI0009005987 Nature of transaction: REDEMPTION OF PLEDGE Transaction details (1): Volume: 1,000 Unit price: N/A Aggregated transactions (1): Volume: 1,000 Volume weighted average price: N/A ____________________________________________ UPM, Media Relations Mon-Fri 9:00–16:00 EEST tel. +358 40 588 3284 media@upm.com UPM We deliver renewable and responsible solutions and innovate for a future beyond fossils across six business
Oma Savings Bank Plc: Manager´s Transactions – Pasi Sydänlammi3.5.2024 11:30:00 CEST | Press release
OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE, 3 MAY 2024 12.30 P.M. EET, MANAGER’S TRANSACTION Oma Savings Bank Plc: Manager´s Transactions – Pasi Sydänlammi Person subject to the notification requirements: Name: Pasi Sydänlammi Position: Chief Executive Officer Issuer: Oma Savings Bank Plc LEI: 743700LE1ECAPXC5UT18 Notification type: INITIAL NOTIFICATION Reference number: 61269/4/5 Transaction date: 2024-05-02 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000306733 Nature of the transaction: ACQUISITION Transaction details (1): Volume: 101 Unit price: 16.94 EUR (2): Volume: 150 Unit price: 16.98 EUR (3): Volume: 91 Unit price: 16.98 EUR (4): Volume: 92 Unit price: 16.98 EUR (5): Volume: 35 Unit price: 16.98 EUR (6): Volume: 189 Unit price: 17.00 EUR (7): Volume: 37 Unit price: 16.98 EUR (8): Volume: 188 Unit price: 17.00 EUR (9): Volume: 40 Unit price: 16.96 EUR (10): Volume: 3 Unit price: 16.96 EUR (11): Volume: 202 Unit price: 16.96 EUR (12): Volume: 99 Unit pric
Resolutions of Meriaura Group Plc's Annual General Meeting and the Board of Directors3.5.2024 11:15:00 CEST | Press release
Meriaura Group Plc Company Announcement 3 May 2024 at am 11.15 (CEST) Resolutions of Meriaura Group Plc's Annual General Meeting and the Board of Directors The Annual General Meeting of Meriaura Group Plc was held on 3 May 2024 in Helsinki. A total of 19 shareholders participated in the meeting, representing 603,765,718 shares, i.e. approximately 69,7 per cent of all shares and votes of the company. Annual accounts for 2023 The General Meeting adopted the annual accounts for the financial period 2023 and resolved not to pay any dividend and that the net profit of the financial period EUR 7,844,371.11 shall be transferred to retained earnings/loss account. Resolution on the discharge from liability of the members of the Board of Directors and the CEO The General Meeting resolved to grant discharge from liability for the members of the Board of Directors and the CEO for the period 1 January 2023 – 31 December 2023 as well as for the preparation of the annual accounts. Resolution on remun
Magna Announces First Quarter 2024 Results3.5.2024 11:00:00 CEST | Press release
Sales increased 3% to $11.0 billion, compared to a 2% rise in global light vehicle productionDiluted earnings per share and Adjusted diluted earnings per share were $0.03 and $1.08, respectivelyRecorded asset impairments and restructuring totaling $316 million related to FiskerPaid dividends of $134 millionMaintaining 2024 Adjusted EBIT Margin Outlook range of 5.4%-6.0% AURORA, Ontario, May 03, 2024 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX: MG; NYSE: MGA) today reported financial results for the first quarter ended March 31, 2024. Please click HERE for full first quarter MD&A and Financial Statements. THREE MONTHS ENDEDMarch 31, 2024March 31, 2023Reported Sales$10,970$10,673 Income from operations before income taxes$34$275 Net income attributable to Magna International Inc.$9$209 Diluted earnings per share$0.03$0.73 Non-GAAP Financial Measures(1) Adjusted EBIT$469$449Adjusted diluted earnings per share$1.08$1.15All results are reported in millions of U.S. dollars, except per